Achievement of the Fifth Medium-Term Management Plan
First written in FY2018. 13 of 17 entries say "Advanced", first in FY2019-Q3. Latest entry: FY2024-Q1.
1 other company's latest entry also says "Advanced".
- FY2024-Q1AdvancedAnnual report
「As of 30 June 2023, the pharmaceutical network had 9,172 members, comprising 430 Group companies and 8,742 general members, an increase of 260 from the end of the previous fiscal year.」
After exceeding the reset target of 7,300 members under the Fifth Medium-Term Management Plan, the number increased to 9,172. - FY2023-Q2AdvancedAnnual report
「As of 30 September 2022, the pharmaceutical network had 8,173 members, comprising 427 Group companies and 7,746 general members, an increase of 772 from the end of the previous fiscal year.」
After exceeding the reset target of 7,300 members for the end of the fiscal year ending March 2022 under the Fifth Medium-Term Management Plan, the number increased to 8,173 by the end of September 2022. - FY2023-Q1AdvancedAnnual report
「As of 30 June 2022, the pharmaceutical network had 7,812 members, comprising 426 Group companies and 7,386 general members, an increase of 411 from the end of the previous fiscal year.」
After exceeding the reset target of 7,300 members for the end of the fiscal year ending March 2022 under the Fifth Medium-Term Management Plan, the number increased to 7,812 by the end of June 2022. - FY2022AdvancedAnnual report
「As of 31 March 2022, the pharmaceutical network had 7,401 members, comprising 425 Group companies and 6,976 general members, an increase of 1,285 from the end of the previous fiscal year.」
The number of members reached 7,401, exceeding the reset target of 7,300 for the end of the fiscal year ending March 2022 under the Fifth Medium-Term Management Plan. This is distinguished from achievement of the plan’s overall financial targets. - FY2022-Q3AdvancedAnnual report
「As of 31 December 2021, the pharmaceutical network had 424 group members and 6,579 general members, for a total of 7,003 members, an increase of 887 from the end of the previous consolidated fiscal year.」
Against the reset target of 7,300 member pharmacies by the end of the fiscal year ending March 2022, the number had reached 7,003 as of the end of December. - FY2022-Q2AdvancedAnnual report
「As of 30 September 2021, the pharmaceutical network had 419 group members and 6,281 general members, for a total of 6,700 members, an increase of 584 from the end of the previous consolidated fiscal year.」
After exceeding the Fifth Medium-Term Management Plan’s 5,000-member target, the number of members reached 6,700 toward the reset target of 7,300 by the end of the fiscal year ending March 2022. - FY2022-Q1AdvancedAnnual report
「As of 30 June 2021, the pharmaceutical network had 6,367 members, comprising 417 Group companies and 5,950 general members, an increase of 251 from the end of the previous fiscal year.」
After the target was reset to 7,300 members by the end of the fiscal year ending March 2022, the number of members reached 6,367. - FY2021Revised targets: lower profit targets and a higher member targetAnnual report
「The target number of pharmaceutical network members was achieved in January 2020, two years ahead of schedule. For the fiscal year ending March 2022, the company will aim for 7,300 member pharmacies at the end of that fiscal year, an increase of 1,184 members.」
The 5,000-member target under the Fifth Medium-Term Management Plan was deemed achieved two years ahead of schedule, and the target for the end of the fiscal year ending March 2022 was raised to 7,300. The company also set out plans to establish a structure aimed at reaching 10,000 member pharmacies. Meanwhile, citing the COVID-19 pandemic and other factors, it lowered its initial forecasts for revenue, operating profit and EBITDA for the fiscal year ending March 2022. - FY2021-Q3AdvancedAnnual report
「As of 31 December 2020, the pharmaceutical network had 413 group members and 5,332 general members, for a total of 5,745 members, an increase of 500 from the end of the previous consolidated fiscal year.」
The number of members continued to increase after exceeding the Fifth Medium-Term Management Plan’s final-year target of 5,000, reaching 5,745. - FY2021-Q2AdvancedAnnual report
「As of 30 September 2020, the pharmaceutical network had 409 group members and 5,227 general members, for a total of 5,636 members, an increase of 391 from the end of the previous consolidated fiscal year.」
The number of members continued to increase after exceeding the Fifth Medium-Term Management Plan’s final-year target of 5,000, reaching 5,636. - FY2021-Q1AchievedAnnual report
「As of 30 June 2020, the pharmaceutical network had 415 group members and 5,202 general members, for a total of 5,617 members, an increase of 372 from the end of the previous consolidated fiscal year.」
The number of members exceeded the Fifth Medium-Term Management Plan’s final-year target of 5,000, reaching 5,617 after the accelerated target date at the end of March 2020. - FY2020-Q3AdvancedAnnual report
「In the pharmaceutical network segment, new memberships continued to progress steadily against the backdrop of growing demand for more efficient distribution. As of 31 December 2019, the pharmaceutical network had 4,922 members, comprising 421 Group companies and 4,501 general members, an increase of 1,132 from the end of the previous fiscal year.」
The number of members under the Fifth Medium-Term Management Plan reached 4,922, leaving a gap of 78 to the accelerated target of 5,000 by the end of March 2020. - FY2020-Q2AdvancedAnnual report
「In the pharmaceutical network segment, new memberships continued to progress steadily against the backdrop of growing demand for more efficient distribution. As of 30 September 2019, the pharmaceutical network had 4,560 members, comprising 419 Group companies and 4,141 general members, an increase of 770 from the end of the previous fiscal year.」
The number of members under the Fifth Medium-Term Management Plan reached 4,560, leaving a gap of 440 to the accelerated target of 5,000 by the end of March 2020. - FY2020-Q1AdvancedAnnual report
「In the pharmaceutical network segment, new memberships continued to progress steadily against the backdrop of growing demand for more efficient distribution. As of 30 June 2019, the pharmaceutical network had 4,118 members, comprising 421 Group companies and 3,697 general members, an increase of 328 from the end of the previous fiscal year.」
The number of members under the Fifth Medium-Term Management Plan reached 4,118. This was below the accelerated target of 5,000 by the end of March 2020, but was up 328 from the end of March 2019. - FY2019RaisedAnnual report
「As of the end of March 2020, the company aimed for 5,000 members, two years ahead of the final-year target for the fiscal year ending March 2022 under the Fifth Medium-Term Management Plan.」
The company explicitly stated its policy of pursuing the Fifth Medium-Term Management Plan’s final-year target of 5,000 members ahead of schedule, by the end of March 2020. - FY2019-Q3AdvancedAnnual report
「As of 31 December 2018, the pharmaceutical network had 3,369 dispensing pharmacies and 61 hospitals and clinics, for a total of 3,430 members, an increase of 921 from the end of the previous consolidated fiscal year, reaching the target of 3,200 members for the end of the current period ahead of schedule.」
The target of 3,200 members for the end of the year under the Fifth Medium-Term Management Plan was achieved ahead of schedule. This does not indicate achievement of the plan as a whole, including the final-year target of 5,000 members. - FY2018First statedAnnual report
「In the “Fifth Medium-Term Management Plan” for the four years beginning April 2018, announced on 8 May 2018, the following targets were set for the final year, the fiscal year ending March 2022: 5,000 pharmaceutical network members; consolidated revenue of ¥120 billion; consolidated operating profit of ¥5 billion; consolidated EBITDA of ¥7.5 billion; and an equity ratio of 30% or higher.」
As a four-year plan covering April 2018 through the fiscal year ending March 2022, the company set targets of 5,000 members, consolidated revenue of ¥120 billion, consolidated operating profit of ¥5 billion, consolidated EBITDA of ¥7.5 billion and an equity ratio of at least 30%. Its basic policies included expanding the network, improving pharmacy quality and primary-care functions, promoting generic drugs, strengthening integrated community care, and enhancing cash flow and the financial position.